Elicio Therapeutics(ELTX)

Search documents
Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024
GlobeNewswire News Room· 2024-12-12 12:00
Core Insights - Elicio Therapeutics presented updated results from the Phase 1 AMPLIFY-201 clinical trial for ELI-002, showing a median recurrence-free survival (mRFS) of 16.3 months and median overall survival (mOS) of 28.9 months in patients with KRAS-mutant tumors [1][3] - A strong correlation was observed between T cell response and mRFS, with ongoing trials expected to provide further insights in H1 2025 [2][3] Company Overview - Elicio Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies for high-prevalence cancers, particularly mKRAS-positive pancreatic and colorectal cancers [4][5] - The company's lead product candidate, ELI-002, is an off-the-shelf cancer vaccine targeting common KRAS mutations, which are implicated in approximately 25% of all solid tumors [5][6] Clinical Trial Details - The AMPLIFY-201 trial enrolled 25 patients, including 20 with pancreatic ductal adenocarcinoma (PDAC) and 5 with colorectal cancer (CRC), all at high risk of relapse after surgery [2][3] - ELI-002 demonstrated a favorable safety profile, with no severe treatment-emergent adverse events reported [3] Efficacy Data - The updated data showed that patients with above-median T cell responses had not yet reached mRFS, while those with below-median responses had a mRFS of 4.0 months [3] - The mOS for the full study cohort was 28.9 months, which is comparable to historical controls for PDAC [3] Future Developments - Elicio is advancing a seven-peptide formulation of ELI-002 (ELI-002 7P) in a randomized Phase 2 study, with interim analysis expected in H1 2025 [2][6] - The company aims to leverage its AMP technology to enhance immune responses and improve patient outcomes in cancer treatment [7][9]
Elicio Therapeutics(ELTX) - 2024 Q3 - Quarterly Report
2024-11-13 21:11
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________ FORM 10-Q _____________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth company ☒ For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES E ...
Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
GlobeNewswire News Room· 2024-11-13 21:05
AMPLIFY-7P Phase 2 randomized study anticipated to complete enrollment in Q4 2024; formal interim analysis of disease-free survival (“DFS”) expected in H1 2025Poster presentation at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual Meeting highlighted AMPLIFY-7P Phase 1a translational data, demonstrating durable T cell response and antigen spreading in patients with KRAS mutant tumorsElicio to provide updated relapse-free survival (“RFS”) and overall survival (“OS”) data from AMPLIFY-201 study in ...
All You Need to Know About Elicio Therapeutics (ELTX) Rating Upgrade to Strong Buy
ZACKS· 2024-10-24 17:02
Elicio Therapeutics (ELTX) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years ...
Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines
GlobeNewswire News Room· 2024-09-13 12:30
BOSTON, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, "Elicio Therapeutics" or "Elicio"), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced upcoming presentations in September and October. The first presentation will take place at the upcoming American Association for Cancer Research ("AACR") Special Conference in Cancer Research: Advances in Pancreatic Cancer Research being held September 15-18, 2 ...
Elicio Therapeutics(ELTX) - 2024 Q2 - Quarterly Report
2024-08-13 20:58
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________ FORM 10-Q _____________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth company ☒ For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHAN ...
Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
GlobeNewswire News Room· 2024-08-13 20:30
• AMPLIFY-7P Phase 1 preliminary disease-free ("DFS") survival demonstrates strong correlation between T cell response and reduced risk of progression or death • AMPLIFY-7P Phase 1 data presented at ASCO demonstrated 100% of patients develop mKRAS-specific Tcell response with ~66% of responses including both CD4+ and CD8+ T cells • Long term follow up of the AMPLIFY-201 Phase 1 study will be terminated, and long term follow up of the AMPLIFY-7P Phase 1 study will be minimized to collect only overall surviva ...
Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering
Newsfilter· 2024-06-28 13:00
BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio Therapeutics" or "Elicio"))), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the pricing of an approximately $11.5 million underwritten public offering of its common stock (or pre-funded warrants to purchase common stock in lieu thereof), and accompanying common warrants to purchase common stock, before deducting underwriting discounts ...
Elicio Therapeutics Announces Proposed Public Offering
Newsfilter· 2024-06-27 20:05
Elicio intends to use the net proceeds from this offering together with its existing cash, cash equivalents and marketable securities, for the advancement of its development pipeline, as well as for working capital and general corporate purposes. differ materially from those expressed or implied in the statements due to a number of factors, including, but not limited to, market risks and uncertainties and the risk that the offering of its securities will not be consummated, and the satisfaction of customary ...
Elicio Therapeutics Announces Proposed Public Offering
GlobeNewswire News Room· 2024-06-27 20:05
BOSTON, June 27, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, "Elicio Therapeutics" or "Elicio"), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that it has commenced an underwritten public offering of its shares of common stock and accompanying common warrants and, in lieu of its shares of common stock to certain investors that so choose, pre-funded warrants to purchase shares of common stock and accomp ...